ArticleJournal of clinical immunology2025
Unresolved Issues in Familial Mediterranean Fever: Is p.R202Q MEFV Variant Potentially Pathogenetic in Unleashing Inflammation?
Article in Journal of clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Exertional leg pain is associated with ıncreased disease activity and musculoskeletal ınvolvement, but not MEFV genotype, in familial Mediterranean fever.Irish journal of medical science · 2026Article
- Comparative analysis of exon 10 and non-exon 10 variants in children with familial mediterranean fever: a retrospective cohort study.European journal of pediatrics · 2026Article
- Diagnostic yield of real-time PCR vs. NGS in pediatric FMF: insights from a Turkish cohort.Open medicine (Warsaw, Poland) · 2026Article
- Late-onset familial Mediterranean fever: A case series of missed diagnoses in pleural effusions.Sage open chronic diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Familial Mediterranean Fever (FMF) is caused by mutations in the MEFV gene, which encodes for pyrin. Although genetic testing is commonly employed for FMF diagnosis, the interpretation of genetic results is often challenging. Therefore, we aimed to functionally characterise the p.R202Q MEFV alteration. Furthermore, we hypothesized that inflammation may affect genomic stability and neutrophilic (N) subsets. A cohort comprising patients with FMF (n = 4), p.R202Q variant (n = 18) and FMF-like (n = 8) were selected from the Outpatient Clinic for Autoinflammatory diseases of Padova University Hospital. Primary monocytes were incubated for 3 h in the presence of LPS or LPS + PKN1/2 inhibitor (UCN-01). Colchicine pretreatment was applied to assess its anti-inflammatory effect. Pro-inflammatory cytokines were measured by ELISA and leukocytes were examined using May-Grünwald-Giemsa staining on blood smears. We did not find significant differences in IL-1 and IL-18 levels in monocytes treated with LPS + UCN-01 between p.R202Q patients and healthy donors (HDs). The levels of IL-1β released from LPS-stimulated patients were higher in p.R202Q patients than in HDs. We found that immature and hypersegmented neutrophils were higher in p.R202Q patients than in HD. Nuclear abnormalities were higher in FMF and p.R202Q patients than in HD. Finally, we found a higher cell rate in leukocytes from p.R202Q patients than in HDs. The p.R202Q variant did not appear to affect pyrin function, albeit these patients presented cytological alterations similar to those observed in FMF patients. These changes may contribute to FMF pathophysiology by influencing inflammation progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.